Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

Q4 2025 Earnings Call February 18, 2026 3:30 AM ESTCompany ParticipantsGunilla Osswald - President & CEOJohanna Fälting ...

Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion –– Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 –– Full-Year GAAP Loss per ...

Q4 2025 Earnings Call February 12, 2026 8:30 AM ESTCompany ParticipantsJoe KostkaFrank Laukien - Chairman, CEO ...

Tiny folds anchoring human skin, called 'rete ridges,' form soon after birth. They show an early-life window that could reshape aging.

Here’s how the candidates responded to Star-Telegram questions about why they deserve your vote in the March 3 primary.

•DSS re-opens cold case of the 2019 disappearance of Idris against ex-govFrom Sola Ojo and Molly Kilete, AbujaThe Economic and Financial Crimes Commission (EFCC) yesterday, drilled former Kaduna State ...

In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce ...

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry giants last year are poised to make further advances in 2026, the chairman ...

This morning, I am joined by James C. Foster, Chair, President and Chief Executive Officer; Birgit H. Gershick, Executive Vice President and Chief Operating Officer; and Michael “Mike” Nau, Senior ...